Ucsf-stanford pediatric device consortium
Active Project Grant Awarded Last action
- Award ID
- P50FD007967
- Recipient
-
The Regents Of The University Of California. San Francisco UEI KMH5K9V7S518
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $7,416,670
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date 63% complete
- Funding agency
- Center for Devices and Radiological Health Food and Drug Administration, Department of Health and Human Services
- Place of performance
- San Francisco, CA 94143, USA
Award details come from USAspending.gov.
Description
- Abstract
- There is a critical clinical and commercial unmet need for novel pediatric devices that are designed specifically for the unique needs of children. The ucsf-stanford pediatric device consortium (PDC) has been a key player in this space since its inception in 2009, with a successful history in supporting over 250 pediatric device innovations in many clinical specialties and in all device classes on their path to commercialization and patient access. In the previous 5-year grant cycle, the ucsf-stanford PDC supported 128 projects in research, development, and engineering, 67 projects in bench and animal testing, 21 projects in intellectual property, 55 projects in regulation, 71 projects in business and commercialization, and 30 projects in payment and reimbursement. This has led to over $100M in collective follow-on funding, 9 commercially available products, and over 20,000 children positively impacted by these technologies. The ucsf-stanford PDC is also proud to be the first PDC to effectively use real-world clinical data and real-world evidence for successful regulatory clearance of a device and label expansion for pediatric use. Ucsf-stanford PDC combines the outstanding resources and unique innovation ecosystems available in two world-class universities and two leading children's hospitals with the unsurpassed entrepreneurial network in the heart of the BAY area, to equip pediatric innovators at all stages of development to translate their innovations into high-value, commercially viable, and equitable products that are accessible to all populations. The PDC is now further expanding its scope and impact through 1) a partnership with world-class device incubator fogarty innovation, 2) the diversification of leadership with actionable plans to promote diversity, equity and inclusion (DEI) in device development, and 3) the expansion of real-world evidence (RWE) consulting and education through a collaborative PDC service center as well as a new partnership with a leading RWE firm, aetion. Two seasoned device innovators, hanmin LEE, MD (pediatric surgeon and surgeon in chief at ucsf benioff children's hospitals) and james wall, MD (pediatric surgeon and biodesign lead, stanford university) will lead the PDC team consisting of device experts with clinical, technical, regulatory, and other relevant expertise. They will be supported by senior medtech industry professionals, multidisciplinary advisory committees, and multiple institutional stakeholders (ucsf-stanford center of excellence in regulatory science and innovation, clinical trials offices, and DEI council),to catalyze promising pediatric device innovations to viable commercial products. Through committed leadership, collective efforts, great resources, and the unique expertise gained from previous grant cycles, the ucsf-stanford PDC will be able to achieve the objectives detailed in the proposal to accelerate many high-impact, value-based pediatric device solutions to commercialization and patient impact. The ucsf- stanford PDC will continue to play a leadership role, along with other pdcs, in creating a national network and ecosystem to foster pediatric device innovations.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,483,334 | |
| Amendment | $1,483,334 | |
| Amendment | $1,483,334 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,483,334 | |
| Original award | $1,483,334 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Heartpoint Global Inc. | $50,000 | |
| Maguro Surgical Inc. | $25,000 | |
| Imagine Devices Inc. | $50,000 | |
| Acqumen Medical, Inc. | $50,000 | |
| Avatar Medtech Corporation | $50,000 | |
| Madison Scientific, Inc. | $25,000 | |
| Acqumen Medical, Inc. | $50,000 | |
| Sonura Care Inc. | $25,000 | |
| Bloom Standard, Inc. | $25,000 | |
| California Institute Of Technology | $50,000 | |
| Heartpoint Global Inc. | $25,000 | |
| Vascular Perfusion Solutions Inc. | $25,000 | |
| Bloom Standard, Inc. | $25,000 | |
| The Leland Stanford Junior University | $25,000 | |
| The Leland Stanford Junior University | $1,050,411 | |
| Subrecipient not on record | $25,000 |
Show all 16
Quick answers
Who received award P50FD007967?
P50FD007967 was awarded to The Regents Of The University Of California. San Francisco by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 1, 2023.
How much is award P50FD007967 worth?
$7,416,670 has been obligated on P50FD007967.
Which agency awarded P50FD007967?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded P50FD007967, with funding from Center for Devices and Radiological Health (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award